Canntab Therapeutics Limited (CTABF)
Canntab Therapeutics Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Markham, ON, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $3,891. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -1257.6%. Its beta of 1.42 implies it has historically moved more than the broad market.
Canntab Therapeutics Limited is a Canadian phytopharmaceutical firm dedicated to pioneering the research and development of sophisticated, pharmaceutical-grade cannabinoid preparations. The company manufactures various oral cannabis medications, including extended-release cannabinoid pills and pellets, rapidly acting cannabidiol formulations, multi-layered modified-release options, quick-dissolving flash-melt products, and dual-layer cannabinoid tablets. These offerings target a broad spectrum of health issues, such as sleep disturbances, post-traumatic stress disorder, social anxiety, various addictions, arthritis, chronic pain, appetite loss and pain linked to cancer therapies, and as an aid in managing dependency on opioids and other painkillers. Canntab Therapeutics Limited operates from its base in Markham, Canada.
Canntab Therapeutics Limited is most often compared with the following Healthcare names: